2021
November
Step aside, DC1s, there’s a new sheriff in town
November 24, 2021
While conventional type 1 DCs (DC1s) are recognized as key drivers of CD8+ T cell antitumor immunity, a variety of antigen-presenting cell (APC) subsets reside within the tumor microenvironment, and their roles remain incompletely understood. Recently reported in Immunity, Duong et al. interrogated the specific contribution of a novel DC subset in mediating...
Myeloid cells provide CD28 costimulation that’s key to overcoming TIL exhaustion
November 17, 2021
Immune checkpoint blockade is a powerful treatment for many cancers, and a number of factors are known to predict or contribute to responses. However, some cancers that seem set up for success, like high-grade serous epithelial ovarian cancer (HGSOC), still fail to respond to therapy. In a recent study published in Cancer Cell...
New dysfunctional TIL family limits checkpoint responses in lung cancer
November 10, 2021
Many non-small cell lung cancer (NSCLC) tumors do not respond to immune checkpoint blockade (ICB), even in the presence of CD8+ tumor-infiltrating lymphocytes (TILs). To explore the mechanisms behind this phenomenon, Horton et al. evaluated T cell phenotypes and functions in orthotopic lung and flank mouse models for NSCLC. Their results were recently...
AACR Tumor Immunology and Immunotherapy 2021
November 3, 2021
In October, the ACIR team attended the virtual AACR Tumor Immunology and Immunotherapy conference 2021. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. Tumor microenvironment and TME-targeted immunotherapyPing-Chih HoGreg M. DelgoffeSaar GillJohanna A. JoyceJennifer L. Guerriero Tumor...
